On Friday, President Trump issued three executive orders (and threatened a fourth) outlining sweeping changes he planned to make regarding prescription drug prices in the United States. One order seeks to make federal grants to federally qualified health centers contingent upon discounted insulin prices. A second would allow personal and wholesale importation of prescription drugs from overseas. The third implements rebate reform for pharmacy benefits managers (PBMs).
FreedomWorks is proud to announce that our bill of the month for June 2019 is the Prescription Drug Price Transparency Act, H.R. 1035, sponsored by Rep. Doug Collins (R-Ga.). The Prescription Drug Price Transparency Act would require greater transparency and accountability from pharmacy benefit managers (PBMs). This would lower prices for patients, families, and caregivers across the United States.
Welcome to FreedomWorks Foundation’s fifth regulatory review of 2019! Our Regulatory Action Center proudly updates you with our favorite tidbits from the swamp. We want to smash barriers between bureaucracy and the American people by delivering regulatory news straight to FreedomWorks activists. Check back in two weeks for the next edition.